Search results for "Neoplasm Recurrence"

showing 10 items of 422 documents

Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma

2003

BACKGROUND. The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports. METHODS. One hundred forty-three patients were evaluated clinically and had favorable Stage IA or IIA Hodgkin lymphoma. Ninety-three patients were treated with the standard VBM schedule combined with extended-field radiotherapy (EFRT), leaving the choice of the therapeutic sequence free. Fifty subsequent patients were treated with a slightly modified VBM schedule (VbMp) combined with RT limited to involved fields (IF-RT) and delivered only after the end of chemotherapy. In the VbMp sched…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPulmonary toxicitymedicine.drug_classmedicine.medical_treatmentchemotherapyBleomycinGastroenterologyAntimetaboliteBleomycinchemistry.chemical_compoundHodgkinPrednisoneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLungradiotherapyAgedChemotherapybusiness.industryHodgkin; chemotherapy; radiotherapy; toxicitytoxicityMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRegimenMethotrexateTreatment OutcomeOncologychemistryVincristineFemaleMethotrexateNeoplasm Recurrence Localbusinessmedicine.drugCancer
researchProduct

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct

Macroscopic assessment of mesorectal excision in rectal cancer

2009

BACKGROUND: High quality of surgical technique and the use of descriptive measures to assess and report surgical proficiency have been shown to influence locoregional tumor control in patients with rectal cancer. In this study, the authors have aimed to audit the implementation of a macroscopic assessment of mesorectal excision (MAME) and to investigate factors that influenced surgical quality and disease recurrence. METHODS: All curative resections for rectal cancer were prospectively evaluated for MAME between 1998 and 2007. Mesorectal specimens were graded into 3 types: complete, nearly complete, and incomplete categories. Univariate and multivariate analyses identified independent risk …

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerMesorectummedicineHumansDigestive System Surgical ProceduresAgedNeoplasm StagingMesorectalAged 80 and overRectal NeoplasmsAbdominoperineal resectionbusiness.industryRectumCancerOdds ratioMiddle Agedmedicine.diseaseTotal mesorectal excisionSurgeryClinical trialTreatment OutcomeOncologyFemaleNeoplasm Recurrence LocalbusinessCancer
researchProduct

Prevalence of patients with colorectal cancer requiring follow-up or active treatment

2008

Abstract Introduction The objective of this study was to estimate prevalence of colorectal cancers requiring care or follow-up. Materials and methods Prevalence was observed in 2005 on the population-based digestive cancer registry of Burgundy (France). Total and 5-year partial prevalences were calculated. The prevalence of patients requiring follow-up was estimated using non-mixture cure models. The prevalence of patients with recurrence was estimated using annual recurrence rates. Results Total prevalence was 262,244 cases in France. The mean variation in 5-year partial prevalence between successive 5-year periods was +8.0%. Time to cure was estimated to be 9.3 years, suggesting that foll…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPopulationPrevalenceInternal medicineEpidemiologyPrevalencemedicineHumansRegistrieseducationSurvival rateAgededucation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseSurgeryCancer registrySurvival RateOncologyFemaleFranceNeoplasm Recurrence LocalColorectal NeoplasmsbusinessEuropean Journal of Cancer
researchProduct

Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer

2011

BACKGROUND: Preoperative chemoradiation is becoming the standard treatment for patients with locally advanced rectal cancer. However, since the introduction of total mesorectal excision (TME), local recurrence rates have been reduced significantly, and some patients can be spared from potentially toxic over treatment. The current study was designed to assess the factors that predict recurrence in an institutional series of patients with rectal cancer who had clinical T2 lymph node-positive (cT2N+) tumors or cT3N0/N+ tumors and underwent radical surgery without receiving preoperative chemoradiation. METHODS: Between November 1997 and November 2008, the authors' multidisciplinary group preope…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaDisease-Free SurvivalmedicineHumansRadical surgerySurvival rateAgedNeoplasm StagingMesorectalAged 80 and overRectal Neoplasmsbusiness.industryStandard treatmentCancerMiddle Agedmedicine.diseaseCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapySurgerySurvival RateRadiation therapyTreatment OutcomeOncologyLymphatic MetastasisFemaleNeoplasm Recurrence LocalbusinessCancer
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct

Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck

1995

Despite considerable progress achieved in the management of head and neck carcinomas (HNC) in the last decade, the prognosis of patients with advanced squamous cell HNC is still dismal. On the basis of the reported good activity of a new vinca alkaloid derivative, i.e., vinorelbine (VNR), we tested the combination of cisplatin and VNR in a series of patients with recurrent or previously untreated unresectable squamous cell HNC. Thirty-five patients with recurrent or previously untreated unresectable squamous cell HNC were treated with a combination of cisplatin 80 mg/m2 on day 1, plus vinorelbine 25 mg/m2 i.v. push on days 1 and 8. This cycle was repeated every 3 weeks. Analysis of response…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentVinblastineVinorelbineGastroenterologyDrug Administration ScheduleVinca alkaloidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCisplatinChemotherapybusiness.industryRemission InductionVinorelbineMiddle AgedVinblastineSurgeryRadiation therapyRegimenOncologyHead and Neck NeoplasmsCarcinoma Squamous CellVomitingFemaleCisplatinNeoplasm Recurrence Localmedicine.symptombusinessmedicine.drug
researchProduct

Enhanced Interleukin-1β Release and Longevity of Glioma-associated Peripheral Blood Monocytes in Vitro

1994

Interleukin-1 (IL-1) plays a controversial role in the immune response. Besides its activation of immune cells and juvenile central nervous system cells, monocyte-derived IL-1 may be able to stimulate the malignant transformation and proliferation of glial brain tumor cells expressing IL-1 receptors. The aim of this study was to determine the growth pattern and the IL-1 beta release of long-term cultured peripheral blood monocytes of glioma patients. At 6- to 7-day intervals, the vital monocytes, characterized by CD14 immunophenotyping, were counted. By the use of a specific IL-1 beta enzyme-linked immunosorbent assay, the IL-1 beta content of monocyte culture supernatants derived from 13 s…

AdultMaleCell SurvivalCD14In Vitro TechniquesMonocytesImmune systemImmunophenotypingReference ValuesGliomaTumor Cells CulturedmedicineHumansAgedBrain Neoplasmsbusiness.industryMonocyteInterleukinMiddle AgedPrognosismedicine.diseaseCell Transformation Neoplasticmedicine.anatomical_structureCell cultureImmunologyFemaleSurgeryNeurology (clinical)Neoplasm Recurrence LocalGlioblastomabusinessCell DivisionInterleukin-1Blood samplingNeurosurgery
researchProduct

Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival

2018

OBJECTIVESpinal ependymomas are rare glial neoplasms. Because their incidence is low, only a few larger studies have investigated this condition. There are no clear data concerning prognosis and therapy. The aim of the study was to describe the natural history, perioperative clinical course, and local tumor control of adult patients with spinal ependymomas who were surgically treated under modern treatment standards.METHODSThe authors performed a multicenter retrospective study. They identified 158 adult patients with spinal ependymomas who had received surgical treatment between January 2006 and June 2013. The authors analyzed the clinical and histological aspects of these cases to identif…

AdultMaleEpendymomaMicrosurgerymedicine.medical_specialtyAdolescentSpinal intradural tumormedicine.medical_treatmentYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceNeoplasmsBiomarkers TumormedicineHumansSpinal Cord NeoplasmsProgression-free survivalGrading (tumors)AgedRetrospective StudiesAged 80 and overSpinal cordbusiness.industryIncidence (epidemiology)Retrospective cohort studyGeneral MedicinePerioperativeMiddle AgedPrognosismedicine.diseaseProgression-Free Survivalddc:616.8SurgeryRadiation therapyKi-67 AntigenLocalOncologyEpendymomaTumor progression030220 oncology & carcinogenesisFemaleRadiotherapy AdjuvantNeoplasm Recurrence Localbusiness030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurosurgery: Spine
researchProduct